sabato, 28 novembre 2020
Medinews
15 Giugno 2018

Expanding the Uses of Cell-Free DNA Assays: From Guiding Treatment Decisions to Applications in Early Disease Detection

Analyzing cell-free DNA (cfDNA) circulating in plasma or serum can help oncologists determine the genotype of tumors noninvasively to guide treatment decisions and may eventually allow them to monitor treatment response, predict recurrence, and screen for cancer. cfDNA is released into the blood following the death of normal and cancer cells, and in patients with cancer the circulating tumor DNA (ctDNA) has been shown to bear the same tumor-related … (leggi tutto)

TORNA INDIETRO